Amends the Public Health Service Act to expand and strengthen federal sickle cell disease activities by changing program language, broadening the types of awards the program may make, and increasing the authorized funding level for sickle cell disease work. It also states the sense of Congress that more research is needed into causes and cures for heritable blood disorders, including sickle cell disease. The change authorizes wider grant or award options for organizations and researchers working on care, treatment, outreach, or research, and signals congressional support for additional research efforts — but it authorizes funding rather than actually appropriating money.
Updated 1 hour ago
Last progress March 3, 2025 (11 months ago)
Updated 2 hours ago
Last progress March 6, 2025 (11 months ago)
Lower Costs for Everyday Americans Act
Updated 1 hour ago
Last progress March 3, 2025 (11 months ago)
Amend paragraph (1)(A)(iii) of Section 1106(b) by replacing the phrase “prevention and treatment of sickle cell disease” with “treatment of sickle cell disease and the prevention and treatment of complications of sickle cell disease.”
Amend paragraph (2)(D) of Section 1106(b) by replacing the phrase “prevention and treatment of sickle cell disease” with “treatment of sickle cell disease and the prevention and treatment of complications of sickle cell disease.”
Amend paragraph (3)(A) of Section 1106(b) by changing the authority language from “enter into a contract with” to “make a grant to, or enter into a contract or cooperative agreement with,” thereby adding grants and cooperative agreements as authorized award types.
Amend paragraph (3)(B), clauses (ii) and (iii), of Section 1106(b) by replacing “prevention and treatment of sickle cell disease” with “treatment of sickle cell disease and the prevention and treatment of complications of sickle cell disease.”
Amend paragraph (6) of Section 1106(b) by striking the authorized amount “$4,455,000 for each of fiscal years 2019 through 2023” and inserting “$8,205,000 for each of fiscal years 2025 through 2029.”
Consolidated Appropriations Act, 2026
Updated 2 hours ago
Last progress February 3, 2026 (3 weeks ago)
Who is affected and how:
People with sickle cell disease: Direct beneficiaries if expanded awards fund clinical care, screening, patient support, or research that leads to improved treatments. Communities with higher sickle cell prevalence (including many Black and Hispanic communities) may see expanded services and research focus.
Researchers and scientific institutions: May gain access to a broader set of federal awards for basic, translational, or clinical research on sickle cell disease and other heritable blood disorders.
Health care providers and community organizations: Could receive new or different types of grants for service delivery, workforce training, outreach, care coordination, or demonstration projects.
Federal agencies (HHS, CDC, NIH and program offices): Must implement the expanded award authorities, set priorities, and potentially issue guidance or new funding opportunity announcements; increased authorized funding gives agencies a higher ceiling but does not guarantee appropriations.
Federal budget process: The change authorizes higher spending levels, so actual program expansion depends on subsequent appropriations; therefore near‑term impact depends on congressional funding decisions.
Overall effect: The amendment makes it easier for a wider range of actors to receive federal support for sickle cell–related activities and signals legislative interest in more research, but practical changes depend on agency implementation and funding availability.
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Last progress February 26, 2025 (12 months ago)
Introduced on February 26, 2025 by Tim Scott